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Abstract 36	
 37	
Cytokine-mediated activation of host immunity is central to the control of pathogens. A 38	
key cytokine in protective immunity is interferon-gamma (IFNg), which is a potent activator of 39	
antimicrobial and immunomodulatory effectors within the host. A major role of IFNg is to induce 40	
major histocompatibility complex class II molecules (MHCII) on the surface of cells, which is 41	
required for CD4+ T cell activation. Despite its central role in host immunity, the complex and 42	
dynamic regulation of IFNg-induced MHCII is not well understood. Here, we integrated functional 43	
genomics and transcriptomics to comprehensively define the genetic control of IFNg-mediated 44	
MHCII surface expression in macrophages. Using a genome-wide CRISPR-Cas9 library we 45	
identified genes that control MHCII surface expression, many of which have yet to be 46	
associated with MHCII. Mechanistic studies uncovered two parallel pathways of IFNg-mediated 47	
MHCII control that require the multifunctional glycogen synthase kinase 3 beta (GSK3b) or the 48	
mediator complex subunit MED16. Both pathways are necessary for IFNg-mediated induction of 49	
the MHCII transactivator CIITA, MHCII expression, and CD4+ T cell activation. Using 50	
transcriptomic analysis, we defined the regulons controlled by GSK3b and MED16 in the 51	
presence and absence of IFNg and identified unique networks of the IFNg-mediated 52	
transcriptional landscape that are controlled by each gene. Our analysis suggests GSK3b and 53	
MED16 control distinct aspects of the IFNg-response and are critical for macrophages to 54	
respond appropriately to IFNg. Our results define previously unappreciated regulation of MHCII 55	
expression that is required to control CD4+ T cell responses by macrophages. These 56	
discoveries will aid in our basic understanding of macrophage-mediated immunity and will shed 57	
light on mechanisms of failed adaptive responses pervasive in infectious disease, autoimmunity, 58	
and cancer.  59	
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Introduction 60	
Activation of the host response to infection requires the coordinated interaction between 61	
antigen presenting cells (APCs) and T cells (1-3). For CD4+ T cells, the binding of the T cell 62	
receptor (TCR) to the peptide-loaded major histocompatibility complex class II (MHCII) on 63	
the surface of APCs is necessary for both CD4+ T cell activation and their continued effector 64	
function in peripheral tissues (3-5). Dysregulation of MHCII control leads to a variety of 65	
conditions including the development autoimmunity and increased susceptibility to pathogens 66	
and cancers (6-10). While MHCII is constitutively expressed on dendritic cells and B cells, the 67	
production of the cytokine IFNg promotes MHCII expression broadly in other cellular populations 68	
including macrophages (11-14). The induction of MHCII in these tissues activates a feedforward 69	
loop wherein IFNg-producing CD4+ T cells induce myeloid MHCII expression, which in turn 70	
amplifies CD4+ T cell responses (14-16). Thus, IFNg-mediated MHCII expression is essential for 71	
protective immunity.   72	
 The IFNg-dependent control of MHCII is complex (5, 12, 17-19). Binding of IFNg to its 73	
receptor induces cytoskeletal and membrane rearrangement that results in the activation of 74	
Janus kinases 1 and 2 (JAK1 and JAK2) and STAT1-dependent transcription (20, 21). STAT1 75	
induces IRF1, which then drives the expression of the MHCII master regulator, CIITA (22, 23). 76	
The activation of CIITA opens the chromatin environment surrounding the MHCII locus and 77	
recruits transcription factors, including CREB1 and RFX5 (5, 24). MHCII is also regulated post-78	
translationally to control the trafficking, peptide loading, and stability of MHCII on the surface of 79	
cells (25-27). While recent evidence points to additional regulatory mechanisms of IFNg-80	
mediated MHCII expression, including the response to oxidative stress, these have not been 81	
investigated directly in macrophages (17).  82	
 In non-inflammatory conditions, macrophages express low levels of MHCII that is 83	
uniquely dependent on NFAT5 (15). While basal MHCII expression on macrophages plays a 84	
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role in graft rejection, it is insufficient to control intracellular bacterial pathogens, which require 85	
IFNg-activation to propagate protective CD4+ T cell responses (28-30). Many pathogens 86	
including Mycobacterium tuberculosis and Chlamydia trachomatis inhibit IFNg-mediated MHCII 87	
induction to evade CD4+ T cell-mediated control and drive pathogen persistence (31-33). 88	
Overcoming these pathogen immune evasion tactics is essential to develop new treatments or 89	
immunization strategies that provide long-term protection (28). Without a full understanding of 90	
the global mechanisms controlling IFNg-mediated MHCII regulation in macrophages, it has 91	
proven difficult to dissect the mechanisms related to MHCII expression that cause disease or 92	
lead to infection susceptibility.  93	
 Here we globally defined the regulatory networks that control IFNg-mediated MHCII 94	
surface expression on macrophages. Using CRISPR-Cas9 to perform a forward genetic screen, 95	
we identified the major components of the IFNg-regulatory pathway in addition to many genes 96	
with no previously known role in MHCII regulation. Follow-up studies identified two critical 97	
regulators of IFNg-dependent CIITA expression in macrophages, MED16 and GSK3b. Loss of 98	
either MED16 or GSK3b resulted in significantly reduced MHCII expression on macrophages, 99	
unique changes in the IFNg-transcriptional landscape, and prevented the effective activation of 100	
CD4+ T cells. These results show that IFNg-mediated MHCII expression in macrophages is 101	
finely tuned through parallel regulatory networks that interact to drive efficient CD4+ T cell 102	
responses.  103	
 104	
  105	
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Results 106	
 107	
Optimization of CRISPR-Cas9 editing in macrophages to identify regulators of IFNg-108	
inducible MHCII. 109	
To better understand the regulation of IFNg-inducible MHCII we optimized gene-editing 110	
in immortalized bone marrow-derived macrophages (iBMDMs) from C57BL6/J mice. iBMDMs 111	
were transduced with Cas9-expessing lentivirus and Cas9-mediated editing was evaluated by 112	
targeting the surface protein CD11b with two distinct single guide RNAs (sgRNA). When we 113	
compared CD11b surface expression to a non-targeting control (NTC) sgRNA by flow 114	
cytometry, we observed less than 50% of cells targeted with either of the CD11b sgRNA were 115	
successfully edited (Figure S1A). We hypothesized that the polyclonal Cas9-iBMDM cells 116	
variably expressed Cas9 leading to inefficient editing. To address this, we isolated a clonal 117	
population of Cas9-iBMDMs using limiting dilution plating. Using the same CD11b sgRNAs in a 118	
clonal population (clone L3) we found 85-99% of cells were deficient in CD11b expression by 119	
flow cytometry compared to NTC (Figure S1B). Successful editing was verified by genotyping 120	
the CD11b locus for indels at the sgRNA targeting sequence using Tracking of Indels by 121	
Decomposition (TIDE) analysis (34). Therefore, clone L3 Cas9+ iBMDMs proved to be a robust 122	
tool for gene editing in murine macrophages. 123	
 To test the suitability of these cells to dissect IFNg-mediated MHCII induction we next 124	
targeted Rfx5, a known regulator of MHCII expression, with two independent sgRNAs (35). We 125	
stimulated Rfx5 targeted and NTC cells with IFNg for 18 hours and quantified the surface 126	
expression of MHCII by flow cytometry (Fig 1A and 1B). In cells expressing the non-targeting 127	
sgRNA, IFNg stimulation resulted in a 20-fold increase in MHCII. In contrast, cells transduced 128	
with either of two independent sgRNAs targeting Rfx5 failed to induce the surface expression of 129	
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MHCII following IFNg stimulation. Thus, L3 cells are responsive to IFNg and can be effectively 130	
used to interrogate IFNg-mediated MHCII expression in macrophages.  131	
 132	
Forward genetic screen identifies known and novel regulators of MHCII surface 133	
expression in macrophages 134	
 To define the genetic networks required for IFNg-mediated MHCII expression, we made 135	
a genome-wide library of mutant macrophages with sgRNAs from the Brie library to generate 136	
null alleles in all protein-coding genes (36). After verifying coverage and minimal skew in the 137	
initial library, we conducted a forward genetic screen to identify regulators of IFNg-dependent 138	
MHCII expression (Figure 1C and Table S1). The loss-of-function library was stimulated with 139	
IFNg and 24 hours later, we selected MHCIIhigh and MHCIIlow expressing cells by fluorescence 140	
activated cells sorting (FACS). Following genomic DNA extraction, sgRNA abundances for each 141	
sorted bin were determined by deep sequencing.  142	
As our knockout library relied on the formation of Cas9-induced indels and was exclusive 143	
to protein-coding genes, we focused our analysis on genes expressed in macrophages under 144	
the conditions of interest, which we determined empirically in the isogenic cell line by RNA-seq 145	
(Table S2). We assumed that sgRNAs targeting non-transcribed genes are neutral in their effect 146	
on IFNg-induced MHCII expression, which afforded us ~32,000 internal negative control 147	
sgRNAs (37). To test for statistical enrichment of sgRNAs and genes, we used the modified 148	
robust rank algorithm (a-RRA) employed by Model-based Analysis of Genome-wide 149	
CRISPR/Cas9 Knockout (MAGeCK), which first ranks sgRNAs by effect and then filters low 150	
ranking sgRNAs to improve gene significance testing (38). We tuned the sgRNA threshold 151	
parameter to optimize the number of significant hits without compromising the calculated q-152	
values of known positive controls that are expected to be required for IFNg-mediated MHCII 153	
expression. Further, by removing irrelevant sgRNAs that targeted genes not transcribed in our 154	
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conditions, we removed potential false positives and improved the positive predictive value of 155	
the screen (Figure S2A and S2B). 156	
Guide-level analysis confirmed the ability to detect positive control sgRNAs which had 157	
robust enrichment in the MHCIIlow population (Fig S2C). Using the previously determined 158	
parameters, we tested for significantly enriched genes that regulated MHCII surface levels. As 159	
expected, sgRNAs targeting known components of the IFNg-receptor signal transduction 160	
pathway, such as Ifngr1, Ifngr2, Jak1 and Stat1, as well as regulators and components of 161	
IFNg-mediated MHCII expression, such as Ciita, Rfx5, and Rfxank were all significantly 162	
enriched (Figure 1D) (5, 22). These results validated our approach to identify functional 163	
regulators of IFNg-mediated MHCII expression.  164	
Stringent analysis revealed a significant enrichment of genes with no known involvement 165	
in interferon responses and antigen presentation. To identify functional pathways that are 166	
associated with these genes, we performed KEGG pathway analysis on the positive regulators 167	
of IFNg-induced MHCII that met the FDR cutoff (FigS2D) (39-41). However, gene membership 168	
for the ten most enriched KEGG pathways was largely dominated by known regulators of IFNg 169	
signaling. To circumvent this redundancy and identify novel pathways enriched from our 170	
candidate gene list, the gene list was truncated to remove the 11 known IFNg signaling 171	
regulators. Upon reanalysis, several novel pathways emerged, including mTOR signaling 172	
(Figure S2E). Thus, our genetic screen uncovered previously undescribed pathways that are 173	
critical to control IFNg-mediated MHCII surface expression in macrophages. 174	
 The results of the genome-wide CRISPR screen highlight the sensitivity and specificity 175	
of our approach and analysis pipeline. To gain new insights into IFNg-mediated MHCII 176	
regulation, we next validated a subset of candidates that were not previously associated with 177	
the IFNg-signaling pathway. Using two independent sgRNAs for each of 15 candidate genes, we 178	
generated loss-of-function macrophages in the L3 clone (Figure 1E and S2F). MHCII surface 179	
.CC-BY-NC-ND 4.0 International license(which was not certified by peer review) is the author/funder. It is made available under a
The copyright holder for this preprintthis version posted August 12, 2020. . https://doi.org/10.1101/2020.08.12.248252doi: bioRxiv preprint 
	 8	
expression was quantified by flow cytometry for each cell line in the presence and absence of 180	
IFNg activation. For all 15 candidates, we observed deficient MHCII induction following IFNg 181	
stimulation with at least one sgRNA. For 9 of15 candidate genes, we observed a significant 182	
reduction in MHCII surface expression with both gene-specific sgRNAs These results show that 183	
our screen not only identified known regulators of IFNg-mediated MHCII induction, but also 184	
uncovered new regulatory networks required for MHCII expression on macrophages.  185	
 We were interested in better understanding the IFNg-mediated transcriptional activation 186	
of MHCII to determine if a subset of candidates reveal new regulatory mechanisms of MHCII-187	
expression. Based on the screen and validation results, we examined the known functions of 188	
the candidates that were confirmed with two sgRNAs, and identified MED16 and Glycogen 189	
synthase kinase 3b (GSK3b) for follow-up study. MED16 is a subunit of the mediator complex 190	
that regulates transcription initiation while GSK3b is a multifunctional kinase that controls 191	
signaling pathways known to regulate transcription (42, 43). Thus, we hypothesized that MED16 192	
and GSK3b would be required for effective IFNg-mediated transcriptional control of MHCII.  193	
 194	
MED16 is uniquely required for IFNg-mediated CIITA expression. 195	
We first examined the role of MED16 in controlling IFNg-mediated MHCII expression. 196	
MED16 was the sixth ranked candidate from our screen results, with robust enrichment of all 4 197	
sgRNAs in the MHCIIlow population (Fig2A). Our validation results confirmed that MED16 was 198	
indeed an essential positive regulator of MHCII expression (Fig1E). As part of the mediator 199	
complex, MED16 bridges the transcription factor binding and the chromatin remodeling that are 200	
required for transcriptional activation (44). These changes then recruit and activate RNA 201	
polymerase II to initiate transcription. While the core mediator complex function is required for 202	
many RNA polymerase II dependent transcripts, distinct sub-units of the mediator complex can 203	
also play unique roles in gene regulation (42, 44). To examine if MED16 was uniquely required 204	
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for IFNg-dependent MHCII expression, we probed our genetic screen data for all mediator 205	
complex subunits. None of the other 27 mediator complex subunits in our library showed any 206	
significant changes in MHCII expression (Figure 2B). To test the specific requirement of 207	
MED16, we generated knockout macrophages in Med16 (Med16 KO) and using two 208	
independent sgRNAs targeted three additional mediator complex subunits, Med1, Med12 and 209	
Med17 (Figure S3 and materials and methods). We treated with IFNg and quantified the surface 210	
levels of MHCII by flow cytometry. In support of the screen results, Med1, Med12 and Med17 211	
showed similar MHCII upregulation compared to NTC cells, while Med16 targeted cells 212	
demonstrated defects in MHCII surface expression (Figure 2C and Figure 2D). These results 213	
suggest that there is specificity to the requirement for MED16-dependent control of IFNg-214	
induced CIITA that is unique among the mediator complex subunits.  215	
 To understand the mechanisms of how MED16 regulates MHCII-induction, we assessed 216	
the transcriptional induction of MHCII in Med16 KO cells. In macrophages, the IFNg-mediated 217	
transcriptional induction of MHCII subunits requires the transcriptional activation of CIITA that 218	
then, in complex with other factors like RFX5, initiates transcription at the MHCII locus (14, 17). 219	
To determine whether MED16 controls the transcriptional induction of MHCII, we stimulated 220	
NTC, Med16 KO and Rfx5 targeted cells with IFNg for 18 hours and isolated RNA. Using qRT-221	
PCR, we observed that loss of RFX5 did not impact the induction of CIITA, but had a profound 222	
defect in the expression of H2-Aa compared to NTC cells (Fig2E). Loss of MED16 significantly 223	
inhibited the induction of both CIITA and H2-Aa. These data suggest that MED16 controls the 224	
induction of MHCII through upstream regulation of CIITA.  225	
  226	
Loss of GSK3b prevents the IFNg-dependent induction of CIITA.  227	
We next examined the mechanisms of GSK3b control of IFNg-mediated MHCII 228	
expression in more detail. GSK3b is involved in many cellular pathways including mTor and Wnt 229	
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(43, 45, 46). While GSK3b was previously suggested to repress collagen production via CIITA, 230	
no role in regulating IFNg-mediated MHCII expression has previously been described (47). In 231	
addition to its high ranking in the screen and the strong effects of multiple sgRNAs (Figure 3A), 232	
pathway analysis uncovered a significant enrichment of genes within the mTor pathway, which 233	
controls GSK3b function, suggesting this signaling network is critical for MHCII expression 234	
(Figure S2E) (46). Our validation studies further showed that GSK3b is required for the effective 235	
induction of IFNg-dependent MHCII (Figure 1E).  To begin to understand the mechanisms 236	
controlling GSK3b-dependent regulation of MHCII expression we generated Gsk3b knockout 237	
cells (Gsk3b KO) and verified that the loss of Gsk3b strongly inhibited IFNg-mediated MHCII 238	
surface expression (Figure 3B and Figure S3B).  239	
  To confirm the genetic evidence using an orthogonal method, GSK3b function was 240	
inhibited chemically using the well-characterized small molecule CHIR99021 (48, 49). NTC 241	
macrophages treated with either CHIR99021 or DMSO were stimulated cells with IFNg and 242	
MHCII expression was analyzed by flow cytometry. Consistent with the genetic experiments, 243	
inhibition of GSK3b activity reduced the induction of surface MHCII, and was similar to a genetic 244	
loss of Gsk3b alone (Figure 3C and 3D). The GSK3b chemical inhibitor facilitated additional 245	
experiments in other cells that were not possible with Med16 KO cells. Thus, we repeated this 246	
experiment in primary bone marrow-derived macrophages from HoxB8 conditionally 247	
immortalized progenitor cells and observed identical results (Figure 3E) (50). Therefore, GSK3b 248	
activity is required for the effective induction of IFNg-mediated MHCII in immortalized and 249	
primary murine macrophages.   250	
We next examined if the IFNg-mediated transcriptional induction of CIITA or H2-Aa were 251	
reduced in Gsk3b KO cells. Loss of GSK3b significantly inhibited the expression of both CIITA 252	
and H2-Aa after IFNg-treatment compared to NTC controls. These data suggest that GSK3b, 253	
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similar to MED16, is an upstream regulator of IFNg-mediated MHCII induction that controls the 254	
expression of CIITA following IFNg-activation.   255	
These qRT-PCR studies (Figure 3F and 3G) suggested that GSK3b was required for the 256	
transcriptional activation of CIITA. We hypothesized that GSK3b inhibition with CHIR99021 257	
would block MHCII expression only if the inhibitor was present shortly after IFNg stimulation. To 258	
test this hypothesis, iBMDMs were stimulated with IFNg then treated with DMSO for the length 259	
of the experiment or with CHIR99021, 2, 6, 12, and 18 hours post-stimulation. When MHCII was 260	
quantified by flow cytometry we saw a reduction in MHCII expression when CHIR99021 was 261	
added two or six hours after IFNg (Figure 3H). CHIR99021 addition at later time points resulted 262	
in similar MHCII expression compared to DMSO treated cells. When the expression of H2-Aa 263	
mRNA was quantified from a parallel experiment, a significant reduction in mRNA expression 264	
was only observed in macrophages that were treated with CHIR99021 two hours following IFNg-265	
activation (Figure 3I). Thus, GSK3b activity is required early after IFNg stimulation to activate the 266	
transcription of MHCII.   267	
 We were interested in understanding the pathways GSK3b regulates that contribute to 268	
CIITA induction. One previous study in Raw264.7 cells found a requirement for GSK3b to 269	
activate STAT3 following IFNg stimulation (51). While STAT1, and not STAT3, is thought to 270	
control the majority of CIITA induction, a minor role for STAT3 remained possible. To test the 271	
contribution of STAT1 and STAT3 to IFNg-induced MHCII, we targeted both Stat1 and Stat3 272	
with two independent sgRNAs to generate loss-of-function macrophages. As expected, when 273	
these cells were stimulated with IFNg, Stat1 prevented the increase of MHCII surface 274	
expression. In contrast, neither sgRNA targeting Stat3 showed any difference in MHCII 275	
expression compared to non-targeting control (Figure S3C). Thus, while GSK3b may regulate 276	
STAT3 dependent pathways following IFNg, a loss in STAT3 functionality does not explain the 277	
contribution of GSK3b to IFNg-mediated MHCII induction. Together these results suggest that 278	
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GSK3b, similarly to MED16, controls IFNg-mediated MHCII expression upstream of the 279	
transcriptional induction of CIITA.  280	
 281	
GSK3a controls IFNg-induced MHCII expression in the absence of GSK3b  282	
Throughout the experiments above we observed that cells treated with CHIR99021 283	
inhibited MHCII even more robustly than the Gsk3b KO cells. CHIR99021 not only inhibits 284	
GSK3b but also the paralog GSk3a (52). This led us to consider the role of GSK3a in IFNg-285	
mediated MHCII expression. While we did not observe enrichment for GSK3a in the screen 286	
(Figure 1D and Table S1), we could not exclude the possibility that GSK3a can play a 287	
secondary function during IFNg-activation. Given the increased inhibition of MHCII with 288	
CHIR99021, we hypothesized that GSK3a can partially compensate for total loss of GSK3b, 289	
resulting in some remaining IFNg-induced MHCII expression. To test this hypothesis, we treated 290	
NTC and Gsk3b KO macrophages with CHIR99021 or DMSO and quantified MHCII surface 291	
expression. Consistent with our previous results, we found robust inhibition of MHCII expression 292	
on NTC macrophages treated with CHIR99021 (Figure 4A and 4B). In support of a minor role 293	
for GSK3a, CHIR99021 treatment of Gsk3b KO macrophages further reduced surface MHCII 294	
expression after IFNg-stimulation.  295	
To exclude the possibility of CHIR99021 off-target effects we next targeted Gsk3a 296	
genetically. To enable positive selection of a second sgRNA, we engineered vectors in the 297	
sgOpti background with distinct resistance markers for bacterial and mammalian selection that 298	
facilitated multiplexed sgRNA cloning (see materials and methods) (53). These vectors could be 299	
used to improve knockout efficiency when targeting a gene with multiple sgRNAs or target 300	
multiple genes simultaneously (Figure S4A). We targeted Gsk3a with two unique sgRNAs in 301	
either NTC or Gsk3b KO macrophages and stimulated the cells with IFNg. Cells targeting Gsk3a 302	
alone upregulated MHCII expression similarly to NTC control cells (Figure 4C and 4D). In 303	
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contrast, targeting Gsk3a in Gsk3b KO macrophages led to a further reduction of MHCII surface 304	
expression, similar to what was observed with CHIR99021 treatment. This same trend was 305	
observed when we examined CIITA mRNA expression after IFNg-activation (Figure 4E). 306	
Therefore, blocking both GSK3a/b function results in a more severe reduction of IFNg-307	
stimulated MHCII expression in macrophages than GSK3b alone. Taken together, we conclude 308	
that GSK3a regulates IFNg-mediated CIITA induction only in the absence of the GSK3b. 309	
 310	
GSK3b and MED16 function through distinct mechanisms to control IFNg-mediated CIITA 311	
expression. 312	
Since the loss of either MED16 or GSK3b reduced IFNg-mediated CIITA transcription, it 313	
remained possible that these two genes control MHCII expression through the same regulatory 314	
pathway. While Med16 KO macrophages are greatly reduced in IFNg-mediated MHCII induction, 315	
there remains a small yet reproducible increase in MHCII surface expression. We determined if 316	
this effect on MHCII expression after IFNg-activation required GSK3 activity by treating with 317	
CHIR99021. While DMSO-treated Med16 KO cells showed a reproducible 2-3 fold increase in 318	
MHCII expression after IFNg stimulation, CHIR99021 treated Med16 KO cells showed no 319	
change whatsoever (Figure 5A and 5B). These results led us to hypothesize that MED16 and 320	
GSK3b control IFNg-mediated CIITA induction and MHCII expression through independent 321	
mechanisms.  322	
 To test this hypothesis, we compared the transcriptional profiles of Med16 KO and 323	
Gsk3b KO cells to NTC cells by performing RNAseq on cells that were left untreated or were 324	
stimulated with IFNg (See materials and methods). Principal component analysis of these 6 325	
transcriptomes revealed distinct effects of IFNg-stimulation (“condition”; PC1) and genotype 326	
(PC2) gene expression (Figure 5C). Both Med16 and Gsk3b knockout macrophages had 327	
distinct transcriptional signatures in the absence of cytokine stimulation, which were further 328	
.CC-BY-NC-ND 4.0 International license(which was not certified by peer review) is the author/funder. It is made available under a
The copyright holder for this preprintthis version posted August 12, 2020. . https://doi.org/10.1101/2020.08.12.248252doi: bioRxiv preprint 
	 14	
differentiated with IFNg-stimulation. The PCA analysis suggested that MED16 and GSK3b 329	
control distinct transcriptional networks in macrophages following IFNg-activation.  330	
Transcriptional analysis confirmed a critical role of GSK3b and MED16 in regulating 331	
IFNg-dependent CIITA and MHCII expression in macrophages compared to NTC controls 332	
(Figure 5D and 5E). However, the extent to which MED16 or GSK3b controlled the overall 333	
response of macrophages to IFNg remained unclear. To directly assess how MED16 and 334	
GSK3b regulate the general response to IFNg, we queried IFNg-regulated genes from our 335	
dataset that are annotated as part of the cellular response to IFNg stimulation 336	
(GeneOntology:0071346). Hierarchical clustering found that, of the 20 most induced IFNg-337	
regulated transcripts, the expression of 8 were unaffected by loss of either GSK3b and MED16 338	
(Figure 5F, Cluster 2). Importantly, these genes included a major regulator of the IFNg 339	
response, IRF1, as well as canonical STAT1-target genes (GBP2, GBP3, GBP5, GBP6 and 340	
GBP7). This suggests that neither GSK3b nor MED16 are global regulators of the IFNg 341	
response in macrophages, but rather are likely to exert their effect on particular genes at the 342	
level of transcription or further downstream. In contrast, only two genes, out the top 20 IFNg-343	
regulated genes, were similarly reduced in both Med16 KO and Gsk3b KO cells (Cluster 4), one 344	
of which was H2-Ab1. This shows that while GSK3b and MED16 both regulate IFNg-mediated 345	
MHCII expression, they otherwise control distinct aspects of the IFNg-mediated response in 346	
macrophages. The remaining clusters from this analysis showed specific changes in either 347	
Med16 KO or Gsk3b KO cells. Clusters 1 and 3 showed a subset of genes that were more 348	
robustly induced in Gsk3b KO cells compared to NTC and Med16 KO cells. These genes 349	
included NOS2, IL12RB1 and chemokines CCL2, CCL3, CCL4, and CCL7. In contrast, Cluster 350	
5 showed a subset of genes that were reduced only in macrophages lacking MED16, including 351	
IRF8 and STAT1; as these effects were modest, and did not reach statistical significance, they 352	
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may be suggestive of an incomplete positive feedforward in which MED16 plays a role. Further 353	
stringent differential gene expression analysis (FDR<0.05, absolute LFC>1) of the IFNg-354	
stimulated transcriptomes identified 69 and 90 significantly different genes for MED16 and 355	
GSK3b respectively. Of these differentially expressed genes (DEGs), eight non-MHCII genes 356	
were shared between MED16 and GSK3b, including five genes that are involved in controlling 357	
the extracellular matrix (MMP8, MMP12, TNN, and CLEC12a). Taken together these results 358	
suggest that while MED16 and GSK3b both regulate IFNg-mediated CIITA and MHCII 359	
expression in macrophages, they otherwise control distinct regulatory networks in response to 360	
IFNg.  361	
We next used the transcriptional dataset to understand what aspects of IFNg-mediated 362	
signaling MED16 and GSK3b specifically control. To resolve the transcriptional landscape of 363	
Med16 KO macrophages and to understand the specific effect that MED16 loss has on the host 364	
response to IFNg, we analyzed the DEGs for upstream regulators whose effects would explain 365	
the observed gene expression signature. The analysis correctly predicted a relative inhibition on 366	
IFNg signaling compared to NTC due to the muted induction of CIITA, H2-Ab1 and CD74. This 367	
analysis also identified signatures of IL-10, STAT3, and PPARg activation that included SOCS3 368	
induction and PTGS2 downregulation (Figure 5G and Figure S5A and S5B). As the DEG 369	
analysis relied on a stringent threshold that filtered the great majority of the transcriptome from 370	
analysis, we sought to incorporate a more comprehensive analysis capable of capturing genes 371	
with more modest effects based on pathway enrichment. To this end, we performed gene set 372	
enrichment analysis (GSEA) using a ranked gene list derived from the differential gene 373	
expression analysis (54). Of the ~10,000 gene sets tested, 11 sets were enriched for NTC + 374	
IFNg and 76 for MED16 + IFNg (FDR<0.1). To reduce pathway redundancy and infer biological 375	
relevance from the gene sets, we consolidated the signal into pathway networks (Figure S5C), 376	
and observed a significant enrichment for genes involved in xenobiotic and steroid metabolism, 377	
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including many cytochrome p450 family members and glutathione transferases. We also 378	
observed an elevated type I interferon transcriptional response in Med16 KO cells stimulated 379	
with IFNg that included components of IFNa/b signal transduction (IFNAR2), transcription 380	
factors (STAT2, IRF7) and antiviral mediators (OAS2, IFITM1, IFITM2, IFITM3, IFITM6) (Figure 381	
5H and 5I). Thus, MED16 is a critical regulator of the overall interferon response in 382	
macrophages.  383	
We next examined the regulatory networks that were specifically controlled by GSK3b. 384	
As observed by the initial PCA (Fig5C), the transcriptional landscape of GSK3b deficient 385	
macrophages was altered in unstimulated cells. We hypothesized that these widespread 386	
differences may alter cellular physiology and explain, in part, the varied responsiveness of 387	
Gsk3b KO cells to IFNg. DEG analysis of unstimulated macrophages identified 284 differentially 388	
expressed genes due to GSK3b loss. Functional enrichment by STRING identified 3 major 389	
clusters that included dysregulation of chemokines, cell surface receptors, growth factor 390	
signaling, and cellular differentiation (FigS5D). We next examined the response of Gsk3b KO 391	
macrophages following IFNg stimulation. GSEA identified a strong enrichment for chemotaxis 392	
and extracellular matrix remodeling pathways including several integrin subunits and matrix 393	
metalloproteinase members. These results suggest that GSK3b is an important regulator of both 394	
macrophage homeostasis and the response to IFNg. Altogether the global transcriptional 395	
profiling suggests that while MED16 and GSK3b are both critical regulators of IFNg-mediated 396	
MHCII expression, they each control distinct aspects of the macrophage response to IFNg.  397	
 398	
Loss of MED16 or GSK3 inhibits macrophage-mediated CD4+ T cell activation.  399	
While the data to this point suggested that MED16 and GSK3b control the IFNg-400	
mediated induction of MHCII, in addition to distinct aspects of the IFNg-response, it remained 401	
unclear how loss of GSK3b or MED16 in macrophages altered the activation of CD4+ T cells. To 402	
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test this, we optimized an ex vivo T cell activation assay with macrophages and TCR-transgenic 403	
CD4+ T cells (NR1 cells) that are specific for the Chlamydia trachomatis antigen Cta1 (55). 404	
Resting NR1 cells were added to non-targeting control macrophages that were untreated, IFNg 405	
stimulated, Cta1 peptide-pulsed, or IFNg-stimulated and Cta1 peptide-pulsed. Five hours later, 406	
we harvested T cells and used intracellular cytokine staining to identify IFNg producing cells by 407	
flow cytometry. Only macrophages that were treated with IFNg and pulsed with Cta1 peptide 408	
were capable of stimulating NR1 cells to produce IFNg (Figure 6A-6C). Additionally, when Rfx5 409	
deficient macrophages were pulsed with peptide in the presence and absence of IFNg, we 410	
observed limited IFNg production by NR1 cells in both conditions suggesting this approach is 411	
peptide-specific and sensitive to macrophage MHCII surface expression.   412	
 We next determined the effectiveness of macrophages lacking GSK3 components to 413	
activate CD4+ T cells. Macrophages deficient in GSK3a, GSK3b or GSK3a/b along with NTC 414	
and RFX5 controls were left untreated or stimulated with IFNg for 16 hours, then all cells were 415	
pulsed with Cta1 peptide. Resting NR1 cells were then added and the production of IFNg by 416	
NR1 cells from each condition was quantified by flow cytometry five hours later. In agreement 417	
with our findings on MHCII expression, loss of GSK3a did not inhibit the production of IFNg by 418	
NR1 cells (Figure 6D-6F). In contrast, Gsk3b KO cells reduced the number of IFNg+ NR1 cells 419	
over two-fold and reduced the mean fluorescence intensity of IFNg production over 4-fold. 420	
Furthermore, macrophages deficient in GSK3a and GSK3b were almost entirely blocked in their 421	
ability to activate IFNg production by NR1 cells. Thus, macrophages deficient in GSK3 function 422	
are unable to serve as effective antigen presenting cells to CD4+ T cells.  423	
 The ex vivo T cell assay was next used to test the effectiveness of Med16 KO 424	
macrophages as APCs. NR1 cells stimulated on IFNg activated Med16 KO macrophages were 425	
reduced in the number of IFNg+ T cells by 10-fold and the fluorescence intensity of IFNg by 100-426	
fold compared to NTC (Figure 6G-GI). Similar to what we observed with MHCII expression, 427	
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there was a small yet reproducible induction of IFNg+ NR1 cells incubated with IFNg-activated 428	
Med16 KO macrophages. We hypothesized that inhibition of GSK3 and MED16 simultaneously 429	
would eliminate all NR1 activation on macrophages. Treatment of Med16 KO macrophages with 430	
CHIR99021 prior to IFNg-stimulation and T cell co-incubation, eliminated the remaining IFNg 431	
production by NR1 cells seen in the DMSO treated Med16 KO condition. Altogether these 432	
results show that GSK3b and MED16 are critical regulators of IFNg mediated antigen 433	
presentation in macrophages and their loss prevents the effective activation of CD4+ T cells.  434	
 435	
  436	
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Discussion  437	
IFNg-mediated MHCII is required for the effective host response against infections. Here, 438	
we used a genome-wide CRISPR library in macrophages to globally examine mechanisms of 439	
IFNg-inducible MHCII expression. The screen correctly identified major regulators of IFNg-440	
signaling, highlighting the specificity and robustness of the approach. In addition to known 441	
regulators, our analysis identified many new positive regulators of MHCII surface expression. 442	
While we validated only a subset of these candidates, the high rate of validation suggests many 443	
new regulatory mechanisms of IFNg-inducible MHCII expression in macrophages. While the 444	
major pathways identified from the candidates in CRISPR screen were related to IFNg-signaling, 445	
we also identified an important role for other pathways including the mTOR signaling cascade. 446	
Within the top 100 candidates of the screen several genes related to metabolism and lysosome 447	
function including LAMTOR2 and LAMTOR4 were found. Given the known effects of IFNg in 448	
modulating host metabolism, these results suggest that the metabolic changes following IFNg-449	
activation of macrophages is critical for key macrophage functions including the surface 450	
expression of MHCII (56). In addition, we found the small lysosome associated GTPase Arl8a is 451	
an important regulator of IFNg-mediated MHCII surface expression. Interestingly, a paralog, 452	
Arl8b, was previously described as a regulator of MHCII and CD1d, by controlling lysosomal 453	
function (57, 58). Future studies will need to dissect the metabolism specific mechanisms that 454	
macrophages use to control the IFNg response, including the regulation of MHCII. 455	
In this study, we focused our follow up efforts from validated candidates on genes that 456	
might control MHCII transcriptional regulation. We identified MED16 and GSK3b as strong 457	
regulators of IFNg-mediated CIITA induction. Using global transcriptomics we found that loss of 458	
either MED16 or GSK3b in macrophages inhibited subsets of IFNg-mediated genes including 459	
MHCII. Importantly, the evidence here strongly supports a model where MED16 and GSK3b 460	
control IFNg-mediated MHCII expression through distinct mechanisms (Figure 7). Our results 461	
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uncover previously unknown regulatory control of CIITA-mediated expression that is biologically 462	
important to activate CD4+ T cells.  463	
MED16 is a subunit of the mediator complex that is critical to recruit RNA polymerase II 464	
to the transcriptional start site (42). While the mediator complex can contain over 20 unique 465	
subunits and globally regulate gene expression, individual mediator subunits control distinct 466	
transcriptional networks by interacting with specific transcription factors (42, 44). Our data 467	
shows that MED16 is uniquely required among the mediator complex for IFNg-mediated MHCII 468	
expression. How MED16 controls CIITA expression remains an open question. One recent 469	
study showed that MED16 controls NRF2 related signaling networks that respond to oxidative 470	
stress (59). A major finding of our MED16 transcriptional analysis was the identification of 471	
several metabolic pathways involved in oxidative stress and xenobiotics. Given the previous 472	
work that described how oxidative stress and the NRF2 regulator Keap1 regulated IFNg-473	
mediated MHCII expression in human melanoma cells, NRF2 regulation and redox 474	
dysregulation could explain a possible mechanism for MED16 control of MHCII (17). Intriguingly, 475	
the effect of MED16 loss was negligible on many STAT1 and IRF1 targets, and, in fact, resulted 476	
in a type I interferon gene signature. Whether this signature is causative of or secondary to the 477	
dysregulated response to type II interferons remains unknown.  478	
Previous studies showed that CDK8, a kinase that can associate with the mediator 479	
complex, controls a subset of IFNg-dependent gene transcription (60). However, our results 480	
strongly support a model where MED16 acts independently of CDK8. Not only was CDK8 not 481	
identified in the initial CRISPR screen, but our transcriptional profiling showed that the major 482	
IFNg-dependent genes controlled by CDK8, TAP1 and IRF1, remain unchanged in Med16 KO 483	
macrophages. Thus, understanding what transcription factors MED16 interacts with in the future 484	
will be needed to fully determine the mechanisms of MED16-dependent transcription and its 485	
control over CIITA and IFNg-mediated gene expression.  486	
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While we hypothesize that MED16 directly controls CIITA transcription, GSK3 likely 487	
regulates MHCII through signaling networks upstream of transcription initiation. GSK3a and 488	
GSK3b are multifunctional kinases that regulate diverse cellular functions including 489	
inflammatory and developmental cascades (43). Our studies found that loss of GSK3b but not 490	
GSK3a blocked efficient IFNg-mediated MHCII expression. However, ours results suggest that 491	
even though GSK3a is not a primary regulator of IFNg-mediated MHCII expression, it can 492	
partially compensate for the loss of GSK3b. Thus, GSK3a and GSK3b are partially redundant in 493	
their control of IFNg-mediated MHCII expression highlighting the interlinked regulation of MHCII. 494	
This finding supports using genetic interactions studies in the future to fully understand the IFNg-495	
mediated regulatory networks in macrophages.   496	
Because GSK3 regulates a range of pathways, careful work will be needed to determine 497	
which GSK3 regulated networks are responsible for controlling CIITA expression. One major 498	
function of GSK3 is to modulate the activation of the Wnt signaling cascade (43). Inhibition or 499	
loss of GSK3 results in the constitutive stabilization of Beta-Catenin and TCF expression. If the 500	
constitutive activation of Beta-catenin and Wnt signaling prevents effective CIITA expression 501	
remains to be determined. Interestingly, another Wnt signaling pathway member FZD4 was 502	
identified in our screen as required for MHCII expression in our screen, supporting a possible 503	
role for Wnt in IFNg-induced MHCII regulation. It is tempting to speculate that Wnt signaling 504	
balances IFNg-induced activation, resulting in distinct MHCII upregulation between cells with 505	
different Wnt activation states. While there is data supporting interactions between Wnt 506	
pathways and Type I IFN during viral infections, this has not been explored yet in the context of 507	
IFNg (61, 62).  508	
Previous studies suggested that GSK3 controls IFNg mediated STAT3 activation, LPS-509	
mediated nitric oxide production, and IRF1 transcriptional activity but our results in 510	
macrophages clearly show these do not explain the requirement for GSK3-dependent MHCII 511	
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expression (51, 63, 64). In contrast, we found no role for STAT3 in IFNg-mediate MHCII 512	
expression and significantly higher expression of inducible Nitric Oxide Synthase in Gsk3b KO 513	
macrophages. In addition, we observed a significant increase in a number of chemokines that 514	
are critical to mobilizing cells to the site of infections. These results show that GSK3 is a central 515	
regulator of the balanced host response during infection, and that targeting GSK3 function is 516	
likely to make the host susceptible to disease. In line with this prediction, GSK3 was recently 517	
found to be co-opted by the Salmonella enterica serovar Typhimurium effector SteE to skew 518	
infected macrophage polarization and allow infection to persist (65, 66). Our results suggest 519	
another possible effect of targeting GSK3 may be the inefficient upregulation of MHCII on 520	
Salmonella-infected macrophages in response to IFNg. While it is known that Salmonella and 521	
other pathogens including M. tuberculosis and C. trachomatis, modulate the expression of 522	
MHCII, the precise mechanisms underlying many of these virulence tactics remains unclear (27, 523	
28). Our screening results provide a framework to test the contribution of each candidate MHCII 524	
regulator during infection with pathogens that target MHCII. These directed experiments would 525	
allow the rapid identification of possible host-pathogen interactions. It will be important to 526	
determine if augmenting specific MHCII pathways identified by our screen overcomes pathogen-527	
mediated inhibition and induces robust MHCII expression to better activate CD4+ T cells and 528	
protect against disease.  529	
Beyond infections, our dataset provides an opportunity to examine the importance of 530	
newly identified MHCII regulators in other diseases such as tumor progression and 531	
autoimmunity. Of course, MHCII is not the only surface marker that is targeted by pathogens 532	
and malignancy. Other important molecules including MHCI, CD40 and PD-L1 are induced by 533	
IFNg stimulation and are targeted in different disease states (67-70). Employing our screening 534	
pipeline for a range of surface markers will identify regulatory pathways that are shared and 535	
unique at high resolution and provide insights into targeting these pathways therapeutically. 536	
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Taken together, the tools and methods developed here identified new regulators of IFNg-537	
inducible MHCII that will illuminate the underlying biology of the host immune response.   538	
 539	
  540	
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METHODS  541	
 542	
Mice 543	
C57BL/6J (stock no. 000664) were purchased from The Jackson Laboratory. NR1 mice were a 544	
gift of Dr. Michael Starnbach (55). Mice were housed under specific pathogen-free conditions 545	
and in accordance with the Michigan State University Institutional Animal Care and Use 546	
Committee guidelines. All animals used for experiments were 6–12 weeks of age. 547	
 548	
Cell culture 549	
Macrophage cell lines were maintained in Dulbecco’s Modified Eagle Medium (DMEM; Hyclone) 550	
supplemented with 5% fetal bovine serum (Seradigm).  Cells were kept in 5% CO2 at 37C. For 551	
HoxB8- conditionally immortalized macrophages, bone marrow from C57BL6/J mice was 552	
transduced with retrovirus containing estradiol-inducible HoxB8 then maintained in media 553	
containing 10% GM-CSF conditioned supernatants, 10% FBS and 10uM Beta-Estradiol as 554	
previously described (50). To generate BMDMs cells were washed 3x in PBS to remove 555	
estradiol then plated in 20% L929 condition supernatants and 10% FBS. 8-10 days later cells 556	
were plated for experiments as described in the figure legends.  557	
 558	
CRISPR Screen and Analysis 559	
The mouse BRIE knockout CRISPR pooled library was a gift of David Root and John Doench 560	
(Addgene #73633) (36). Using the BRIE library, 4 sgRNAs targeting every coding gene in mice 561	
in addition to 1000 non-targeting controls (78,637 sgRNAs total) were packaged into lentivirus 562	
using HEK293T cells and transduced in L3 cells at a low multiplicity of infection (MOI <0.3) and 563	
selected with puromycin two days after transduction. Sequencing of the input library showed 564	
high coverage and distribution of the library (FigS1). We next treated the library with IFNg 565	
(10ng/ml) and 24 hours later the cells were fixed and fluorescence activated cell sorting (FACS) 566	
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was used to isolate the MHCIIhigh and MHCIIlow bins. Bin size was guided by the observed 567	
phenotypes of positive control sgRNAs, such as RFX5, which were tested individually and to 568	
ensure sufficient coverage (>25x unselected library) in the sorted populations. Genomic DNA 569	
was isolated from sorted populations from two biological replicate experiments using Qiagen 570	
DNeasy kits. Amplification of sgRNAs by PCR was performed as previously described using 571	
Illumina compatible primers from IDT (36), and amplicons were sequenced on an Illumina 572	
NextSeq500.  573	
Sequence reads were first trimmed to remove any adapter sequence and to adjust for p5 574	
primer stagger. We used bowtie 2 via MAGeCK to map reads to the sgRNA library index without 575	
allowing for any mismatch. Subsequent sgRNA counts were median normalized to control 576	
sgRNAs in MAGeCK to account for variable sequencing depth. Control sgRNAs were defined 577	
as non-targeting controls as well as genes not-transcribed in our macrophage cell line as 578	
determined empirically by RNA-seq (Table S2). To test for sgRNA and gene enrichment, we 579	
used the ‘test’ command in MAGeCK to compare the distribution of sgRNAs in the MHCIIhigh and 580	
MHCIIlow bins. Notably, we included the input libraries in the count analysis in order to use the 581	
distribution of sgRNAs in the unselected library for the variance estimation in MAGeCK.  582	
 583	
sgRNA cloning 584	
sgOpti was a gift from Eric Lander & David Sabatini (Addgene plasmid #85681) (53). Individual 585	
sgRNAs were cloned as previously described (71). Briefly, annealed oligos containing the 586	
sgRNA targeting sequence were phosphorylated and cloned into a dephosphorylated and 587	
BsmBI (New England Biolabs) digested SgOpti (Addgene#85681) which contains a modified 588	
sgRNA scaffold for improved sgRNA-Cas9 complexing. A detailed cloning protocol is available 589	
in supplementary methods. To facilitate rapid and efficient generation of sgRNA plasmids with 590	
different selectable markers, we further modified the SgOpti vector such that the mammalian 591	
selectable marker was linked with a distinct bacterial selection. Subsequent generation of 592	
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SgOpti-Blasticidin-Zeocin (BZ), SgOpti-Hygromycin-Kanamycin (HK), and SgOpti-G418-593	
Hygromycin (GH) allowed for pooled cloning in which a given sgRNA was ligated into a mixture 594	
of BsmBI-digested plasmids. Successful transformants for each of the plasmids were selected 595	
by plating on ampicillin (SgOpti), zeocin (BZ), kanamycin (HK), or hygromycin (GH) in parallel. 596	
In effect, this reduced the cloning burden 4x and provided flexibility with selectable markers to 597	
generate near-complete editing in polyclonal cells and/or make double knockouts.  598	
 599	
Flow cytometry 600	
Cells were harvested at the indicated times post-IFNg stimulation by scrapping to ensure intact 601	
surface proteins. Cells were pelleted and washed with PBS before staining for MHCII.  MHCII 602	
expression was analyzed on the BD LSRII cytometer or a BioRad S3E cell sorter. All flow 603	
cytometry analysis was done in FlowJo V9 or V10 (TreeStar) 604	
 605	
Chemical inhibitors 606	
CHIR99021 (Sigma) was resuspended in DMSO at 10 mM stock concentration.  DMSO was 607	
added at the same concentration to the inhibitors as a control.  Cells were maintained in 5% 608	
CO2. Cells were stimulated with 6.25ng/ml of IFNg (Biolegend) for the indicated times in each 609	
figure legend before analysis.  610	
 611	
Isolation of Knockout cells 612	
Cells transduced with either MED16 or GSK3b sgRNAs were stimulated with IFNg then stained 613	
for MHCII 24 hours later. Cells expressing low MHCII were then sorted using a BioRad S3e cell 614	
sorter and plated for expansion. Gene knockouts were confirmed by amplifying the genomic 615	
regions encoding either MED16 or GSK3b from each cell population in addition to NTC cells 616	
using PCR. PCR products were purified by PCR-cleanup Kit (Qiagen) and sent for Sanger 617	
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Sequencing (Genewiz). The resultant ABI files were used for TIDE analysis to assess the 618	
frequency and size of indels in each population compared to control cells.   619	
 620	
RNA isolation 621	
Macrophages were homogenized in 500uL of TRIzol reagent (Life Technologies) and incubated 622	
for 5 minutes at room temperature. 100uL of chloroform was added to the homogenate, 623	
vortexed, and centrifuged at 12,000 x g for 20 minutes at 4C to separate nucleic acids. The 624	
clear, RNA containing layer was removed and combined with 500uL of ethanol. This mixture 625	
was placed into a collection tube and protocols provided by the Zymo Research Direct-zol RNA 626	
extraction kit were followed. Quantity and purity of the RNA was checked using a NanoDrop and 627	
diluted to 5ng/uL in nuclease-free water.  628	
 629	
RNA-sequencing Analysis 630	
To generate RNA for sequencing, macrophages were seeded in 6-well dishes at a density of 1 631	
million cells/well. Cells were stimulated for 18 hours with IFNg (Peprotech) at a final 632	
concentration of 6.25 ng/mL, after which RNA was isolated as described above. RNA quality 633	
was assessed by qRT-PCR as described above and by TapeStation (Aligent); the median RIN 634	
value was 9.5 with a ranger of 8.6 to 9.9. A standard library preparation protocol was followed to 635	
prepare sequencing libraries on poly-A tailed mRNA using the NEBNext® Ultra™ RNA Library 636	
Prep Kit for Illumina®. In total, 18 libraries were prepared for dual index paired-end sequencing 637	
on a HiSeq 2500 using a high-output kit (Illumina) at an average sequencing depth of 38.6e6 638	
reads per library with > 93% of bases exceeding a quality score of 30. FastQC (v0.11.5) was 639	
used to assess the quality of raw data. Cutadapt (v2.9) was used to remove TruSeq adapter 640	
sequences with the parameters  --cores=15 -m 1 -a 641	
AGATCGGAAGAGCACACGTCTGAACTCCAGTCA -A 642	
AGATCGGAAGAGCGTCGTGTAGGGAAAGAGTGT. A transcriptome was prepared with the 643	
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rsem (v1.3.0) command rsem-prepare-reference using bowtie2 (v2.3.5.1) and the gtf and 644	
primary Mus musculus genome assembly from ENSEMBL release 99. Trimmed sequencing 645	
reads were aligned and counts quantified using rsem-calculate-expression with standard 646	
bowtie2 parameters; fragment size and alignment quality for each sequencing library was 647	
assessed by estimating the read start position distribution (RSPD) via --estimate-rspd. Gene 648	
counts as determined by rsem were used as input for differential expression analysis in DESeq2 649	
according to standard protocols. Briefly, counts were imported using tximport (v1.16.0) and 650	
differential expression was performed with non-targeting control ("NTC") and unstimulated 651	
("Condition A") as reference levels for contrasts. For visualization via PCA, a variance stabilizing 652	
transformation was performed in DESeq2. Pathway enrichment utilized R packages gage and 653	
fgsea or Ingenuity Pathway Analysis (Qiagen). Gene-set enrichment analysis (GSEA) was 654	
performed utilized gene rank lists as calculated from defined comparisons in DeSeq2 and was 655	
inclusive of gene sets comprised of 10-500 genes that were compiled and made available by 656	
the Bader lab (72). Pathway visualization and network construction was performed in 657	
CytoScape 3.8 using the apps STRING and EnrichmentMap. Pathway significance thresholds 658	
were set at an FDR of 0.1 unless specified otherwise.  659	
 660	
Quantitative real time PCR 661	
PCR amplification of the RNA was completed using the One-step Syber Green RT-PCR Kit 662	
(Qiagen). 25ng of total RNA was added to a master mix reaction of the provided RT Mix, Syber 663	
green, gene specific primers (5uM of forward and reverse primer), and nuclease-free water. For 664	
each biological replicate (triplicate), reactions were conducted in technical duplicates in 96-well 665	
plates. PCR product was monitored using the QuantStudio3 (ThermoFisher). The number of 666	
cycles needed to reach the threshold of detection (Ct) was determined for all reactions. Relative 667	
gene expression was determined using the 2^-ddCT method. The mean CT of each 668	
experimental sample in triplicate was determined. The average mean of glyceraldehyde 3-669	
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phosphate dehydrogenase (GAPDH) was subtracted from the experimental sample mean CT 670	
for each gene of interest (dCT). The average dCT of the untreated control group was used as a 671	
calibrator and subtracted from the dCT of each experimental sample (ddCT). 2^-ddCT shows 672	
the fold change in gene expression of the gene of interest normalized to GAPDH and relative to 673	
to untreated control (calibrator).  674	
 675	
T cell activation assays 676	
CD4+ T cells were harvested from the lymph nodes and spleens of naive NR1 mice and 677	
enriched with a mouse naïve CD4 negative isolation kit (BioLegend) following the 678	
manufacturer’s protocol. CD4+ T cells were cultured in media consisting of RPMI 1640 679	
(Invitrogen), 10% FCS, l-glutamine, HEPES, 50 μM 2-ME, 50 U/ml penicillin, and 50 mg/ml 680	
streptomycin. NR1 cells were activated by coculture with mitomycin-treated splenocytes pulsed 681	
with 5 μM Cta1133–152 peptide at a stimulator/T cell ratio of 4:1. Th1 polarization was achieved by 682	
supplying cultures with 10 ng/ml IL-12 (PeproTech, Rocky Hill, NJ) and 10 μg/ml anti–IL-4 683	
(Biolegend) One week after initial activation resting NR1 cells were co-incubated with untreated 684	
or IFNg-treated macrophages of different genotypes, that were or were not pulsed with Cta1 685	
peptide. Six hours following co-incubation NR1 cells were harvested and stained for intracellular 686	
IFNg (BioLegend) using an intracellular cytokine staining kit (BioLegend) as done previously. 687	
Analyzed T cells were identified as live, CD90.1+ CD4+ cells.  688	
 689	
Statistical Analysis and Figures 690	
Statistical analysis was done using Prism Version 7 (GraphPad) as indicated in the figure 691	
legends. Data are presented, unless otherwise indicated, as the mean +/- the standard 692	
deviation. Figures were created in Prism V7 or were created with BioRender.com 693	
 694	
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Figure Legends 704	
 705	
Figure 1. Genome-wide CRISPR Cas9 Screen Identifies regulators of IFNg-dependent 706	
MHCII expression. 707	
 708	
(A) Cas9+ iBMDMs (Clone L3) expressing the indicated sgRNAs were left untreated or treated 709	
with IFNg (6.25ng/ml) for 24 hours. Surface MHCII was quantified by flow cytometry. Shown is a 710	
representative histogram of MHCII surface staining and (B) the quantification of the mean 711	
fluorescence intensity (MFI) in the presence and absence of IFNg stimulation from 3 biological 712	
replicates. **** p<.0001 by one-way ANOVA with tukey correction for multiple hypotheses. 713	
These data are representative of three independent experiments. (C) A schematic 714	
representation of the CRISPR-Cas9 screen conducted to identify regulators of IFNg-inducible 715	
MHCII surface expression on macrophages. A genome-wide CRISPR Cas9 library was 716	
generated in L3 cells using sgRNAs from the Brie library (4 sgRNAs per gene). The library was 717	
treated with IFNg and MHCIIhi and MHCIIlow populations were isolated by FACS. The 718	
representation of sgRNAs in each population in addition to input library were sequenced. (D) 719	
Shown is score for each gene in the CRISPR-Cas9 library that passed filtering metrics as 720	
determined by the alpha-robust rank algorithm (a-RRA) in MAGeCK from two independent 721	
screen replicates. (E) The L3 clone was transduced with the indicated sgRNAs for candidates (2 722	
per candidate gene) in the top 100 candidates from the CRISPR-Cas9 screen. All cells were left 723	
untreated or treated with 10ng/ul of IFNg for 24 hours then were analyzed by flow cytometry. 724	
The fold-increase in MFI was calculated for triplicate samples for each cell line (MFI IFNg+/MFI 725	
IFNg-). The results are representative of at least two independent experiments. Candidates that 726	
were significant for two sgRNAs (Red) or one sgRNA (Blue) by one-way ANOVA compared to 727	
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the mean of NTC1 and NTC2 using Dunnets multiple comparison test. Non-significant results 728	
are shown in Grey bars.  729	
 730	
 731	
Figure 2. The mediator complex sub-unit MED16 is uniquely required for IFNg-mediated 732	
MHCII surface expression. 733	
 734	
(A) Shown is the normalized mean read counts from FACS sorted MHCIIlow and MHCIIhi 735	
populations for the four sgRNAs targeting MED16 within the genome-wide CRISPR-Cas9 736	
library. (B) The mean of the log fold change (normalized counts in MHCIIhi/normalized counts in 737	
MHCIIlow) for each mediator complex subunit that passed quality control metrics described in 738	
materials and methods. The bar colors indicate the number of sgRNAs out of four possible that 739	
pass the alpha cutoff using the MAGeCK analysis pipeline as described in material and 740	
methods. (C) Med16 KO cells or L3 cells targeted with the indicated sgRNA were left untreated 741	
or were treated with 6.25 ng/ml of IFNg for 18 hours. Cells were then analyzed for surface 742	
MHCII expression by flow cytometry. Shown are representative comparing the MHCII surface 743	
expression of indicated mediator complex subunit (Black solid line) treated with IFNg overlayed 744	
with NTC (Grey dashed line) treated with IFNg.  (D) Quantification of the MFI of surface MHCII 745	
from the experiment in (C) from three biological replicates. These results are representative of 746	
two independent experiments. (E) NTC L3 cells, RFX5 sg#1 cells, and Med16 KO cells were left 747	
untreated or were treated with 6.25 ng/ml of IFNg. 18 hours later cells RNA was isolated and 748	
qRT-PCR was used to determine the relative expression of CIITA and (H) H2aa compared to 749	
GAPDH controls from three biological replicates. The results are representative of three 750	
independent experiments. ***p<.001 as determined one-way ANOVA compared to NTC cells 751	
with a dunnets test. 752	
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 753	
 754	
Figure 3. Inhibition of GSK3b results in decreased IFNg-mediated CIITA and MHCII 755	
expression.  756	
 757	
(A) Shown is the normalized mean read counts from FACS sorted MHCIIlo and MHCIIhi 758	
populations for the four sgRNAs targeting Gsk3b within the genome-wide CRISPR-Cas9 library. 759	
(B) NTC L3 cells and Gsk3b KO cells were treated with 6.25 ng/ml of IFNg. 18 hours later cells 760	
were stained for surface MHCII and analyzed by flow cytometry. Shown is a representative flow 761	
cytometry plot overlaying Gsk3b KO (blue line) with NTC (grey line). The results are 762	
representative of 5 independent experiments. (C) NTC L3 cells or Gsk3b KO were treated with 763	
DMSO or 10µM CHIR99021 as indicated then left untreated or stimulated with IFNg for 18 764	
hours. MHCII surface expression was then quantified by flow cytometry. A representative flow 765	
cytometry plot of DMSO treated IFNg treated NTC cells is overlaid with either NTC CHIR99021 766	
treated cells (Left) or Gsk3b KO DMSO treated cells (Right). (D) The mean fluorescence 767	
intensity was quantified from three biological replicates. These results are representative of 768	
three independent experiments. (E) Bone marrow derived macrophages from conditionally 769	
immortalized HoxB8 progenitor cells from C57BL6/J mice were treated with DMSO or 10 µM 770	
CHIR99021 and left untreated or stimulated with IFNg for 18 hours. The MHCII surface levels 771	
were then quantified by flow cytometry. Shown is the mean fluorescence intensity from 3 772	
biological replicates in each condition. (F) NTC L3 cells, Rfx5 sg#1 cells, and Gsk3b KO cells 773	
were left untreated or were treated with 6.25ng/ml of IFNg. 18 hours later cells RNA was 774	
isolated and qRT-PCR was used to determine the relative expression of CIITA and (G) H2-Aa 775	
compared to GAPDH controls from three biological replicates. The results are representative of 776	
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three independent experiments. (H) Immortalized bone marrow macrophages were treated with 777	
IFNg. Control cells were treated with DMSO and for the remaining cells CHIR999021 was added 778	
at the indicated times following IFNg treatment. 24 hours after IFNg stimulation the levels of 779	
surface MHCII were quantified by flow cytometry. Shown is the MFI for biological triplicate 780	
samples. (I) In parallel to (H), 24 hours after IFNg stimulation RNA was isolated and the relative 781	
expression of H2-Aa was quantified relative to GAPDH from biological triplicate samples. The 782	
data are representative of three independent experiments.  ***p<.001 **p<.01 *p<.05 by one-783	
way ANOVA with a Tukey Correction test.  784	
 785	
 786	
Figure 4. GSK3a controls IFNg-mediate MHCII expression only in the absence of GSK3b. 787	
 788	
(A) NTC L3 cells or Gsk3b KO were treated with DMSO or 10uM CHIR99021 then left untreated 789	
or stimulated with IFNg for 18 hours. MHCII surface expression was then quantified by Flow 790	
cytometry. A representative flow cytometry plot of DMSO treated IFNg treated NTC cells 791	
(Dashed line) is overlaid with either NTC (Left) or Gsk3b KO (Right) treated with CHIR99021. 792	
The mean log fold change in MFI (IFNg-treated/untreated) was quantified from three biological 793	
replicates. These results are representative of three independent experiments. (C) L3 cells or 794	
Gsk3b KO transduced with the indicated sgRNAs were treated with IFNg and 18 hours later the 795	
surface levels of MHCII were quantified by flow cytometry. A representative histogram of NTC 796	
cells (dotted line) is overlaid with cells targeted with the indicated sgRNA (solid line) after 18 797	
hours of IFNg treatment. In (D) the mean fluorescence intensity of surface MHCII was quantified 798	
from 3 biological replicates from this experiment.  (E) L3 cells or Gsk3b KO transduced with the 799	
indicated sgRNAs were treated with IFNg and 18 hours later RNA was isolated and the 800	
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expression of CIITA was quantified relative to GAPDH using qRT-PCR. Results are from three 801	
independent wells and are representative of two independent experiments. ***p<.001, **p<.01,  802	
*p<.05 by one-way ANOVA with a Tukey correction test.  803	
 804	
Figure 5. Transcriptomic analysis reveals distinct regulatory mechanisms of IFNg 805	
signaling mediated by MED16 and GSK3b.  806	
 807	
(A) Med16 KO cells were treated with DMSO or CHIR99021 then left untreated or stimulated 808	
with IFNg overnight. The following day MHC II cell surface expression was determined by flow 809	
cytometry. Shown is a representative histogram with the indicated treatment in untreated 810	
(Grey/Black line) or IFNg-treated (Colored line) cells. (B) The quantification of the MFI of MHCII 811	
from four biological replicates. ***p<.001 by one-way ANOVA with Tukey correction. (C) The 812	
Global transcriptomes of NTC, Gsk3b KO and Med16KO was determined in the presence and 813	
absence of IFNg-stimulation for 18 hours by RNA sequencing. Shown is the principal 814	
component analysis of the transcriptomes from three biological replicates for each condition. (D) 815	
Dotplot showing the normalized read counts for CIITA and (E) H2-Aa (F) Shown is a heatmap 816	
showing the relative expression (log normalized, row-scaled) of the most varied 20 genes 817	
involved in the cellular response to type II interferon (Gene Ontology GO:0071346). (G) Shown 818	
is a Dotplot visualizing the normalized counts of the type I IFN signature Socs3 from all RNAseq 819	
conditions. Clustering was used to (H) Significant gene sets from Med16 KO cells that were 820	
uniquely regulated from the RNAseq dataset were analyzed by gene set enrichment analysis 821	
(GSEA) then subjected to Leading Edge analysis, which identified a significant enrichment of 822	
the cellular responses to type I interferons (normalized enrichment score 2.81, FDR<0.01). (I) 823	
Shown is a heatmap demonstrating the relative expression of the type I interferon signature 824	
identified in IFNg-stimualted Med16 KO macrophages from the RNAseq analysis. (J) Shown is a 825	
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heatmap demonstrating the relative expression of unique differentially expressed genes from 826	
the Gsk3b KO in the presence (Top) and absence (Bottom) of IFNg-stimulation. (K) These 827	
differentially expressed genes were used in GSEA to identify Leading Edge networks that are 828	
specific to Gsk3b KO cells. (Top) Shown is the leading-edge analysis of the UPAR pathway that 829	
was identified from IFNg-stimulated Gsk3b KO cells. (Bottom) Shown is the leading-edge 830	
analysis of the Granulocyte chemotaxis pathway that was identified as differentially regulated in 831	
resting Gsk3b KO cells.   832	
 833	
Figure 6. IFNg-stimulated macrophages require MED16 or GSK3 to activate CD4+ T cells. 834	
 835	
(A) Macrophages were left untreated, treated with 10ng/ml IFNg overnight, 5µM peptide for 1 836	
hour or both IFNg and peptide as indicated. TCR-transgenic NR1 CD4+ T cells specific for the 837	
peptide Cta1 from Chlamydia trachomatis were then added to L3 macrophages of the indicated 838	
genotypes at a 1:1 ratio. 4 hours after the addition of T cells, NR1 cells were harvested and the 839	
number of IFNg-producing CD4+ T cells was quantified by intracellular staining and flow 840	
cytometry. Shown is a representative flow cytometry plot gated on live/CD4+ cells. Gates for 841	
IFNg+ T cells were determined using an isotype control antibody. (B) The percent of live CD4+ T 842	
cells producing IFNg and (C) the MFI of IFNg production by live CD4+ T cells was quantified 843	
from triplicate samples. These results are representative of three independent experiments. (D) 844	
L3 cells targeted with the indicated sgRNAs were left untreated or treated overnight with IFNg 845	
then pulsed with Cta1 peptide for 1 hour. NR1 cells were then added at a 1:1 ratio and 4 hours 846	
later NR1 cells were harvested and the number of IFNg-producing CD4+ T cells was quantified 847	
by intracellular staining and flow cytometry. Shown is a representative flow cytometry plot gated 848	
on live/CD4+ cells. Gates for IFNg+ T cells were determined using an isotype control antibody. 849	
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(E) The percent of live CD4+ T cells producing IFNg and (F) the MFI of IFNg production by live 850	
CD4+ T cells was quantified from triplicate samples. These results are representative of three 851	
independent experiments. (G) NTC L3 cells or Med16 KO cells were left untreated or treated 852	
overnight with DMSO, IFNg and DMSO or IFNg and CHIR999021 then pulsed with Cta1 peptide 853	
for 1 hour. NR1 cells were then added at a 1:1 ratio and 4 hours after the addition of T cells, 854	
NR1 cells were harvested and the number of IFNg-producing CD4+ T cells was quantified by 855	
intracellular staining and flow cytometry. Shown is a representative flow cytometry plot gated on 856	
live/CD4+ cells. Gates for IFNg+ T cells were determined using an isotype control antibody. (H) 857	
The percent of live CD4+ T cells producing IFNg and (I) the MFI of IFNg production by live CD4+ 858	
T cells was quantified from triplicate samples. These results are representative of three 859	
independent experiments.  860	
 861	
Figure 7. Model of GSK3b- and Med16-mediated control of IFNg-activated MHCII 862	
expression. Shown is a model of how GSK3b and MED16 regulate IFNg-mediated MHCII 863	
expression. In the absence of IFNg (Left) GSK3b controls the transcription of many macrophage 864	
genes related to inflammation such as CCLs. In contrast, Med16 KO cells shows minimal 865	
transcriptional changes in resting macrophages. Additionally, IFNg-mediated gene expression is 866	
low. Following the activation of macrophages with IFNg (Right), STAT1 becomes 867	
phosphorylated and translocates to the nucleus to drive gene transcription. The IFNg-mediated 868	
induction of IRF1 does not require either GSK3b or MED16. While GSK3b continues to 869	
negatively regulate inflammatory genes like CCLs it also positively regulates the transcriptional 870	
activation of CIITA following IFNg-activation. Through a parallel but distinct mechanism, IFNg-871	
mediated induction of CIITA also requires MED16 function. The expression of CIITA then 872	
.CC-BY-NC-ND 4.0 International license(which was not certified by peer review) is the author/funder. It is made available under a
The copyright holder for this preprintthis version posted August 12, 2020. . https://doi.org/10.1101/2020.08.12.248252doi: bioRxiv preprint 
	 38	
recruits other transcription factors such as RFX5 to the MHCII locus where it induces the 873	
expression of MHCII, which allows for the activation of CD4+ T cells.  874	
 875	
Figure S1. Optimization of CRISPR-Cas9 editing in iBMDMs. Immortalized C57BL6/J 876	
macrophages were transduced with lentivirus expressing Cas9 then selected using Hygromycin. 877	
Polyclonal transductants were then transduced with a second lentivirus encoding two different 878	
sgRNAs targeting CD11b or a non-targeting control then selected with puromycin. (A) 879	
Transductants were then stained for surface CD11b one-week later and analyzed by flow 880	
cytometry. Shown is a representative histogram of CD11b from the polyclonal Cas9 line. (B) 881	
Single cell clones were isolated from the polyclonal Cas9 line by limiting dilution. One 882	
clone, clone L3 was transduced with two different sgRNAs targeting CD11b or a non-targeting 883	
control then selected with puromycin. Transductants were then stained for surface CD11b one-884	
week later and analyzed by flow cytometry. Shown is a representative histogram of CD11b from 885	
the L3 Cas9 clone.  886	
 887	
Figure S2. Adaptations to the MAGeCK analysis pipeline identifies high confidence 888	
regulators of IFNg-mediated MHCII expression following a Genome-wide CRISPR Cas9 889	
screen.  890	
 891	
 (A) At the selected alpha cutoff of 0.025, the number of significant genes by FDR level and the 892	
number of false positives (gray bar within black bar) when using all guides; proportion of 893	
significant genes that were false positives annotated above each bar (left half). This analysis 894	
was repeated using only transcribed genes as determined by RNAseq analysis (Table S2). (B) 895	
Genes that passed quality filtering and were expressed within L3 cells at the RNA level as 896	
determined by transcriptomics were ranked by the FDR as determined in MAGeCK. Highlighted 897	
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in Red are the top hits many of which are within the canonical IFNg-signaling and MHCII 898	
expression pathway. Vertical dotted lines indicate genes that are below a calculated FDR of .2 899	
and include the follow-up candidates Med16 and GSK3b. (C) The distribution of sgRNAs based 900	
on the Log2-Fold Change as determined by MAGeCK from three groups of sgRNA targets; 901	
Positive controls (Known IFNg/MHCII pathway), Test Guides (all targeting guides in BRIE library) 902	
and non-targeting controls (~1000 included in BRIE library) are shown. Positive control sgRNAs 903	
are left shifted compared to negative controls indicating an enrichment in the MHCIIlow 904	
population of these sgRNAs. (D) Significant genes from the genome-wide screen were used to 905	
identify enriched pathways from the KEGG pathway database. Shown are the top 10 enriched 906	
pathways from the screen results indicating a significant enrichment of IFNg-related pathways 907	
ranked by FDR and the size of the circle indicates the Normalized Enrichment Score. (E) To 908	
identify new pathways unrelated to IFNg signaling KEGG pathway enrichment was repeated 909	
with the top 11 genes related to IFNg removed from the query list. Shown are the top 10 910	
pathways that were identified by KEGG ranked by FDR and the size of the circle indicates the 911	
Normalized Enrichment Score. (F) The L3 clone was transduced with the indicated sgRNAs for 912	
candidates in the top 100 candidates from the CRISPR-Cas9 screen. All cells were treated with 913	
10ng/ul of IFNg for 24 hours then were analyzed by flow cytometry. Shown are representative 914	
flow cytometry plots from the data quantified in Figure 1E. The results are representative of at 915	
least two independent experiments. *p<.05 **p<.01 ***p<.001 by one-way ANOVA compared to 916	
the mean of NTC1 and NTC2 using Dunnets multiple comparison test.  917	
 918	
Figure S3. Confirmation of KO lines using TIDE analysis. Genomic DNA was isolated 919	
from NTC, Med16 KO and Gsk3b KO cells and the PCR was used to amplify the region 920	
encoding either Med16 or GSK3b. TIDE analysis was used to quantify the editing efficiency of 921	
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the indels in each cell line using trace plots following Sanger sequencing. Shown is the TIDE 922	
analysis profile indicating the percent editing efficiency for (A) Med16 KO and (B) Gsk3b KO 923	
cells compared to NTC control cells. (C) L3 cells and cells transduced with sgRNAs targeting 924	
either Stat1 or Stat3 were left untreated or were stimulated with IFNg for 18 hours. The surface 925	
levels of MHCII were then quantified by flow cytometry and the mean fluorescence intensity 926	
was determined from triplicate samples. These results are representative of two independent 927	
experiments. ***p<.001 by one-way ANOVA compared using Dunnets multiple comparison test 928	
compared to L3 controls.  929	
   930	
Figure S4. Development of a multi-vector sgRNA system to rapidly edit one gene or 931	
simultaneously edit multiple genes. (A) Shown is a schematic of the sgOpti derivatives that 932	
were generated. sgOpti_V1 was previously published and contains an ampicillin bacterial 933	
selection marker and a puromycin mammalian selction marker. sgOpti_V2 and sgOpti_V3 were 934	
generated by subcloning distinct bacterial and mammalian selections markers to deliver multiple 935	
sgRNAs to cells expressing sgOpti_V1. sgOpti_V2 contains a Kanamycin bacterial selection 936	
marker and a Hygromycin B mammalian selection maker while sgOpti_V3 contains a zeocin 937	
bacterial selection marker and a Blasticidin mammalian selection marker. (B) Cells transduced 938	
with the indicated sgRNAs or a clonal IFNgR KO were left untreated or treated with IFNg for 24 939	
hours and analyzed by flow cytometry for the surface expression of the IFNg-inducible marker 940	
CD271. Shown is the percent of cells that induced CD271 compared to untreated cells for each 941	
cell line.  942	
 943	
Figure S5. Transcriptomic analysis of MED16 and GSK3b reveals mechanisms of IFNg-944	
mediated control. (A) RNAseq analysis of NTC, Gsk3b KO and Med16 KO cells was 945	
completed as described in the materials and methods. Shown are representative scatter plots of 946	
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normalized absolute read counts for genes that were highly variable among the conditions from 947	
the heatmap in Figure 5F. (B) Differential gene expression analysis from MED16 KO cells 948	
following IFNg treatment was used to identify dysregulated pathways using gene set enrichment 949	
analysis (GSEA).  Shown are visual representations of the pathway networks identified using 950	
EnrichmentMap and CytoScape. We found a strong downregulation (Blue) of genes involved in 951	
antigen processing and presentation and an upregulation (Red) in genes related to Xenobiootic 952	
metabolism, glutathione activity, and serine hydrolase and matrix metalloprotease activity. (C) 953	
GSEA of differentially expressed genes in the Med16 KO after IFNg-stimulation identified a type 954	
I IFN signature. Shown is a pathway map generated by ingenuity pathway analysis highlighting 955	
the genes that are downregulated (Blue) or upregulated (Orange) in the Type I IFN pathway. 956	
The darkness of the color indicates the magnitude of the differential expression. (D) Differential 957	
expression analysis of the Gsk3b KO in untreated conditions were used in GSEA. Shown is a 958	
visual representation of the dysregulated genes placed into pathway networks using CytoScape. 959	
Genes that are upregulated are shown in Red and downregulated genes are shown in Blue. The 960	
darkness of the shading indicates the magnitude of the change as determined in the RNAseq 961	
analysis.    962	
 963	
Table S1. CRISPR Screen Analysis 964	
 965	
Table S2. RNAseq Analysis  966	
 967	
Table S3. Oligonucleotides used in the study 968	
  969	
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